In this subanalysis of 13,026 participants (mean age, 65 years 70% men), Agarwal and colleagues combined FIDELITY data with data from the National Health and Nutrition Examination Survey to simulate the population-level number of CV events prevented per year with finerenone among patients with type 2 diabetes and CKD. if all eligible patients were treated with finerenone.” FIDELIO-DKD and FIGARO-DKD trialsįor the present study, Agarwal and colleagues used data from the FIDELITY pooled analysis of patients from the FIDELIO-DKD and FIGARO-DKD trials of finerenone (Kerendia, Bayer) on top of maximized renin-angiotensin system inhibition.Īs Healio previously reported, results from the FIDELIO-DKD trial showed that finerenone delayed chronic kidney disease (CKD) progression among adult patients with type 2 diabetes compared with placebo, and results of the FIGARO-DKD trial showed that finerenone reduced CV event risk by 13%, a finding driven by significant reduction in HF hospitalization. We then estimated the population-wide benefit in the U.S. “In patients with type 2 diabetes, we tested whether the cardiovascular disease risk associated with chronic kidney disease, as defined jointly by estimated glomerular filtration rate and albuminuria, was modifiable with finerenone treatment. Thus, the modifiability of chronic kidney disease-associated cardiovascular risk in patients with type 2 diabetes in a broader population - even with estimated glomerular filtration rate of 60 or greater and defined by albuminuria - remains unknown,” the researchers wrote. However, the study considered kidney function (as assessed by estimated glomerular filtration rate) but not kidney damage (albuminuria) in the recruitment strategy. “The modifiability of cardiovascular risk among patients with chronic kidney disease has been demonstrated with the use of simvastatin-ezetimibe in the Study of Heart and Renal Protection (SHARP) trial. ![]() Roudebush VA Medical Center, and colleagues posited that urine albumin-to-creatinine ratio screening could improve outcomes among finerenone-eligible patients.įinerenone could modify chronic kidney disease-associated cardiovascular risk in patients with type 2 diabetes. Rajiv Agarwal, MD, MBBS, MS, professor of medicine at the Indiana University School of Medicine and physician scientist at the Richard L. ![]() Albuminuria screening may improve CV benefits of finerenone in this population.įinerenone, a nonsteroidal mineralocorticoid receptor antagonist, may improve CV risk among patients with type 2 diabetes and kidney disease and those with albuminuria, according to a FIDELITY substudy published in JAMA Cardiology.Finerenone could modify chronic kidney disease-associated cardiovascular risk in patients with type 2 diabetes.If you continue to have this issue please contact to Healio Key takeaways:
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |